Intermediate Endemicity Research Articles

Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis.

Comprehensive details on Hepatitis C virus (HCV) infection in Myanmar are lacking. This study determined the prevalence of HCV antibodies and ribonucleic acid (RNA) and the distribution of HCV genotypes across different populations in Myanmar from 1990 to 2023. A systematic search in PubMed, Web of Science, Scopus, and local journals identified studies reporting on HCV antibodies, RNA, and genotypes, excluding clinical research related to liver disease prognosis. Screening and data extraction was done by two authors and study populations were categorized into low-risk, high-risk, liver disease patients, and refugees outside the country. The pooled prevalence was performed by Dersimonian and Laird method using the R program. The publication bias was shown by funnel plot, the Egger test was used to assess the symmetry of the plot, and the heterogeneity was examined by the Cochran Q test and I2 index. Out of 135 reports screened for eligibility, 35 reports comprising 51 studies were included in which 33 studies provided data on HCV seroprevalence in 685,403 individuals, 8 studies reported HCV RNA prevalence in 25,018 individuals, and 10 studies examined HCV genotypes in 1,845 individuals. The pooled seroprevalence of HCV among low-risk, high-risk, liver disease patients and refugees were 2.18%, 37.07%, 33.84%, and 2.52% respectively. HCV RNA-positive rates in these groups were 1.40%, 5.25%, 24.96%, and 0.84% respectively. Seroprevalence studies showed publication bias (Egger test, p = 0.0001), while RNA studies did not (Egger test, p = 0.8392). HCV genotype 3 was predominant in all sub-groups in Myanmar. Our study shows Myanmar has intermediate HCV endemicity with lowest HCV prevalence of 2.18% in low-risk groups and highest prevalence of 37.07% in high- risk groups. However, the findings highlight the need for further epidemiological studies to understand actual disease burden and implement effective countermeasures to achieve the WHO's goal of HCV elimination by 2030.

Hepatitis B virus infection among illegal drug users in Enugu State, Nigeria: prevalence, immune status, and related risk factors

IntroductionHepatitis B virus infection poses a global health challenge, particularly in low- and middle-income African countries. Illicit drug use exacerbates the problem, with drug users having a higher HBV infection risk and maintaining a quiet transmission pool. This study aimed to determine HBV infection prevalence, immune status, and risk factors among illegal drug users in Enugu State, Nigeria.Materials and methodsA cross-sectional study was conducted in Enugu State, using privileged access interviewer methods to enroll drug users. Pre-tested structured questionnaires were administered after informed consent was obtained. Blood samples were tested for HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb using immunochromatographic rapid test kits. Statistical analysis was performed using SPSS version 25.ResultsOne hundred drug users were recruited into the study. Overall, 7% of the drug users had HBV infection. 61% were found to be susceptible to HBV infection, 15% showed serological evidence of immunity from HBV vaccination and 1% developed natural immunity from HBV exposure. Significant risk factors for HBV infection were age less than 20 years, young age (≤ 20 years) at drug initiation, being single, injecting drugs more than or equal to 20 times per month and injecting with used syringes.ConclusionThis study shows high intermediate endemicity of HBV infection among drug users, low vaccination uptake, and high susceptibility to HBV infection. This calls for the urgent inclusion of drug users in national HBV vaccination campaigns and the adoption of the World Health Organization’s recommendations on the prevention of viral hepatitis among people who inject drugs.

IJCM_298A: Assessment of Knowledge, Attitude and Practice about Hepatitis B among Medical Students

Background: Hepatitis B is a major public health problem. India is in the intermediate HBV endemicity zone (HBsAg prevalence among the general population ranges from 2% to 8%) with 50 million cases which makes it the second largest global pool of chronic HBV infection. Health workers, especially physicians and medical students are always in direct contact with patients and are vulnerable to acquire Hepatitis B infection. Present study aims to evaluate Knowledge, Attitude and Practice (KAP) towards Hepatitis B infection and vaccination among medical students. Objective: To evaluate the knowledge, attitude, and practice (KAP) of medical students regarding Hepatitis B infection and vaccination. Methodology: This was a cross sectional study conducted in Government Medical College. Junior resident and medical undergraduates were involved to assess their Knowledge, Attitude and Practice (KAP) about Hepatitis B infection and vaccination using a self-administered questionnaire. Results: Out of 317 participants 44.4% were males and 55.6% were females. 97.2% medical students have heard about the Hep B infection. 97.8% respondents indicated that they were aware of availability of a vaccine for hepatitis B. 54.6% (173) of total participants had received the Hepatitis B vaccination, of which only 142(82.08%) had received 3 doses of Hepatitis B vaccination. Conclusion: More than 50% of the surveyed participants have been vaccinated indicates a positive trend in immunization. Further efforts are needed to ensure complete vaccination especially in high-risk medical professionals.

Modelling the Cost-Effectiveness of Hepatitis A in South Africa.

The World Health Organization (WHO) recommends the consideration of introducing routine hepatitis A vaccination into national immunization schedules for children ≥ 1 years old in countries with intermediate HAV endemicity. Recent data suggest that South Africa is transitioning from high to intermediate HAV endemicity, thus it is important to consider the impact and cost of potential routine hepatitis A vaccination strategies in the country. An age-structured compartmental model of hepatitis A transmission was calibrated with available data from South Africa, incorporating direct costs of hepatitis A treatment and vaccination. We used the calibrated model to evaluate the impact and costs of several childhood hepatitis A vaccination scenarios from 2023 to 2030. We assessed how each scenario impacted the burden of hepatitis A (symptomatic hepatitis A cases and mortality) as well as calculated the incremental cost per DALY averted as compared to the South African cost-effectiveness threshold. All costs and outcomes were discounted at 5%. For the modelled scenarios, the median estimated cost of the different vaccination strategies ranged from USD 1.71 billion to USD 2.85 billion over the period of 2023 to 2030, with the cost increasing for each successive scenario and approximately 39-52% of costs being due to vaccination. Scenario 1, which represented the administration of one dose of the hepatitis A vaccine in children < 2 years old, requires approximately 5.3 million vaccine doses over 2023-2030 and is projected to avert a total of 136,042 symptomatic cases [IQR: 88,842-221,483] and 31,106 [IQR: 22,975-36,742] deaths due to hepatitis A over the period of 2023 to 2030. The model projects that Scenario 1 would avert 8741 DALYs over the period of 2023 to 2030; however, it is not cost-effective against the South African cost-effectiveness threshold with an ICER per DALY averted of USD 21,006. While Scenario 3 and 4 included the administration of more vaccine doses and averted more symptomatic cases of hepatitis A, these scenarios were absolutely dominated owing to the population being infected before vaccination through the mass campaigns at older ages. The model was highly sensitive to variation of access to liver transplant in South Africa. When increasing the access to liver transplant to 100% for the baseline and Scenario 1, the ICER for Scenario 1 becomes cost-effective against the CET (ICER = USD 2425). Given these findings, we recommend further research is conducted to understand the access to liver transplants in South Africa and better estimate the cost of liver transplant care for hepatitis A patients. The modelling presented in this paper has been used to develop a user-friendly application for vaccine policy makers to further interrogate the model outcomes and consider the costs and benefits of introducing routine hepatitis A vaccination in South Africa.

Epidemiological Profile of Tuberculosis in Tunisia

Abstract Introduction Tuberculosis (TB) is still a public health problem causing significant morbidity in several countries. In 2020, TB was the second global leading cause of death from an infectious disease, behind COVID-19. Despite the continuous efforts of the national tuberculosis control program, Tunisia remains a country with intermediate tuberculosis endemicity. The objective of this study was to describe the incidence of tuberculosis from 2018 to 2021 and its epidemiological profile in Tunisia. Methods This is a descriptive study of the national tuberculosis surveillance data within the framework of the national tuberculosis control programme. All new confirmed cases notified and registered for treatment were included. Data was entered through a registration and notification platform (WEB TBS), which is available in all governorates. Data collected included age, gender, governorate, clinical form. Data analysis was using SPSS-21. Results The incidence rate decreased from 28/100,000 inhabitants in 2018 to 22.46/100,000 inhabitants in 2021. In 2021, 2647 new cases were recorded. The majority were aged between 15 and 64 years old (80.4%). More than half were females (52.4%). There was an increasing trend of extra-pulmonary tuberculosis. It affected 64.6% of cases in 2021, mainly lymph node forms (68.5%). The incidence varied considerably by region; from 59.3/ 100,000 inhabitants in Ariana to 7.3/ 100,000 inhabitants in Monastir (2021). The number of reported cases of co-infection (TB-HIV) increased from 0.09 to 0.14/100,000 inhabitants. Conclusions Despite the overall decline, there is still a long way to go to reach the target of ending TB by 2030. More adherence to control activities is needed in the most affected regions, including early case detection, patient monitoring and epidemiological investigations. There is also an urgent need to develop an effective strategy to control lymph node tuberculosis, which becomes an increasing burden on the national program. Key messages • From 2018 to 2021, there was a national decline in TB incidence, but some regions remain highly endemic. • With the increase of extra-pulmonary tuberculosis, appropriate preventive and control measures should be taken.

Effect of obligatory Hepatitis B vaccination program on the prevalence of occult hepatitis B among pregnant women in Egypt: A cross sectional study

Hepatitis B virus (HBV) infection is a global health problem. HBV is of intermediate endemicity in Egypt. “Occult” HBV (OBI) indicates replication of HBV-DNA in the liver of individuals with negative serum HBsAg. This study aimed to determine the prevalence of OBI among pregnant women in Egypt and to compare this prevalence among HBV vaccinated and unvaccinated women (received obligatory vaccination). This cross-section study included 474 pregnant women in the third trimester divided in two groups. Group I: (n=247) assumed received obligatory hepatitis B vaccination and group II: (n=227), did not receive HBV vaccination. Study participants were screened for HBsAg, anti HBs, anti HBc total, anti HBc IgM, HBeAg, anti HBe, HCV Ab, and HIV Ab by immunoassays and HBV-DNA by Real-Time PCR. Anti HBs was detected in 65 (13.7%) of pregnant women, 36 (14.6%) in the vaccinated group and 29 (12.8%) in the unvaccinated group. The anti HBs levels were significantly higher in the unvaccinated group. HBc Ab showed positive results in 6 cases (2.4%) in the vaccinated group, and 14 cases (6.2%) in unvaccinated group. HBcAb and/or HBsAb were detected in 72 (15.1%) of pregnant women, 39 (15.8%) in the vaccinated group and 33 (14.5%) in the unvaccinated group. HBV-DNA was detected only in one vaccinated pregnant woman. HB vaccination program in Egypt, since 1992 affected the frequency of OBI in pregnant women (p=0.04). In conclusion, HBV infection may persist lifelong in the hepatocytes even when viral functions are suppressed, HBsAb and anti-HBc-positive individuals are present. The levels of HBsAb were higher in unvaccinated pregnant women compared to vaccinated pregnant women. HBV infection in OBI pregnant women may not transmit to the new-born.

Hepatitis A virus infection.

Hepatitis A is a vaccine-preventable infection caused by the hepatitis A virus (HAV). Over 150 million new infections of hepatitis A occur annually. HAV causes an acute inflammatory reaction in the liver that usually resolves spontaneously without chronic sequelae. However, up to 20% of patients experience a prolonged or relapsed course and <1% experience acute liver failure. Host factors, such as immunological status, age, pregnancy and underlying hepatic diseases, can affect the severity of disease. Anti-HAV IgG antibodiesproduced in response to HAV infection persist for life and protect against re-infection; vaccine-induced antibodies against hepatitis A confer long-term protection. The WHO recommends vaccination for individuals at higher risk of infection and/or severe disease in countries with very low and low hepatitis A virus endemicity, and universal childhood vaccination in intermediate endemicity countries. To date, >25 countries worldwide have implemented such programmes, resulting in a reduction in the incidence of HAV infection. Improving hygiene and sanitation, rapid identification of outbreaks and fast and accurate intervention in outbreak control are essential to reducing HAV transmission.

Association of ambient PM2.5 concentration with tuberculosis reactivation diseases—an integrated spatio-temporal analysis

ObjectivesWhile the plausible role of ambient particulate matter (PM)2.5 exposure in tuberculosis (TB) reactivation has been inferred from in vitro experiments, epidemiologic evidence is lacking. We examined the relationship between ambient PM2.5 concentration and pulmonary TB (PTB) in an intermediate TB endemicity city dominated by reactivation diseases. MethodsSpatio-temporal analyses were performed on TB notification data and satellite-based annual mean PM2.5 concentration in Hong Kong. A total of 52,623 PTB cases from 2005-2018 were mapped to over 400 subdistrict units. PTB standardized notification ratio by population subgroups (elderly aged ≥65, middle-aged 50-64, and young adults aged 15-49) was calculated and correlated with ambient PM2.5 concentration. ResultsSignificant associations were detected between high ambient PM2.5 concentration and increased PTB among the elderly. Such associations were stable to the adjustment for socio-economic factors and other criteria pollutants. Unstable patterns of association between PM2.5 and PTB risk were observed in the middle-aged population and young adults, for which the observed associations were confounded by other criteria pollutants. ConclusionWith elderly PTB almost exclusively attributable to reactivation, our findings suggested that increased TB reactivations have occurred in association with high ambient PM2.5 exposure, lending support to preventive measures that minimize PM2.5-related TB reactivation.

Seroprevalence and Associated Risk Factors for Hepatitis B Virus among Pregnant Women Attending a Public Health Facility in Osogbo, Nigeria

BackgroundHepatitis B virus (HBV) infection among pregnant women has a high rate of vertical transmission and consequential effects on fetal and neonatal outcomes. The aim of this study was to determine the prevalence and associated risk factors of infection among pregnant women attending antenatal care services in Osogbo, Nigeria.MethodologyThis hospital based cross-sectional study was conducted among pregnant women attending routine antenatal care clinic between April and June 2021. Systematic random sampling technique was used to recruit 240 pregnant women, their data were collected by face to face interview using a pretested questionnaire, while blood sample was collected aseptically to determine hepatitis B surface antigen by enzyme linked immunosorbent assay test kit. Univariate and multivariate logistic regression were used to examine the association between explanatory variables and outcome variable.ResultsThe mean age and seroprevalence of the study population were 27.50 ± 4.4 years and 5.8% respectively. The significant risk factors for HBV infection were tattooing (aOR = 5.22; 95% CI = 0.52–8.01; p = 0.0000), history of multiple sexual partners (aOR = 2.88; 95% CI = 1.92–12.42; p = 0.0044); and past history of contact with HBV patient (aOR = 2.17; 95% CI = 1.21–15.32; p = 0.0310) were significant predictors of HBV infection.ConclusionThe seroprevalence of HBV from this study was of intermediate endemicity. We therefore, advocate for continuous health education programs on the mode of HBV transmission, high-risk behaviors and methods of preventions at antenatal care clinics to raise the awareness of mothers and limit the spread of infection.Rwanda J Med Health Sci 2023;6(2):199-207

The Changing Epidemiology of Viral Hepatitis in a Post-Soviet Country-The Case of Kyrgyzstan.

Historically, viral hepatitis has been a considerable public health problem in Central Asian countries, which may have worsened after the dissolution of the Soviet Union. However, up-to-date seroepidemiological studies are lacking. The aim of the present study was, therefore, to provide current estimates of the seroprevalence of viral hepatitis in Kyrgyzstan, one of the economically least developed countries in the region. We conducted a population-based cross-sectional study in 2018 in the capital of Kyrgyzstan, Bishkek (n = 1075). Participants, children and adults, were recruited from an outpatient clinic. The data were collected during face-to-face interviews. A blood sample (6 mL) was collected from each participant and tested with ELISA for the presence of serological markers for five viral hepatitides (A, B, C, D, and E). Post-stratification weighing was performed to obtain nationally representative findings. The overwhelming majority of the study participants were positive for anti-HAV (estimated seroprevalence, 75.3%; 95% confidence interval, 72.5-77.9%). The weighted seroprevalence estimates of HBsAg, anti-HCV, and anti-HDV were 2.2% (1.5-3.3%), 3.8% (2.8-5.1%), and 0.40% (0.15-1.01%), respectively. Anti-HEV seropositivity was 3.3% (2.4-4.5%). Of the 33 HBsAg-positive participants, five (15%) were anti-HDV-positive. Our study confirms that Kyrgyzstan remains a highly endemic country for hepatitis virus A and C infections. However, seroprevalences of HBV and HDV were lower than previously reported, and based on these data, the country could potentially be reclassified from high to (lower) intermediate endemicity. The observed anti-HEV seroprevalence resembles the low endemicity pattern characteristic of high-income countries.

Hepatitis B Virus Immunity Gap: A Six-Year Laboratory Data Review of Hepatitis B Serological Profiles in Gauteng Province, South Africa.

In 1995, the hepatitis B vaccine in South Africa was incorporated into the childhood expanded programme of immunization. We report on immunity gaps of laboratory-based hepatitis B virus (HBV) among patients in public facilities in Gauteng Province from 1st January 2014 to 31st December 2019. Methodology. We analyzed HBV serological data extracted from the National Health Laboratory Services Central Data Warehouse (NHLS CDW). A descriptive analysis was performed for hepatitis B surface antigen (HBsAg), antibodies to HBV core (anti-HBc) total, anti-HBc IgM, and antibodies to HBV surface antigen (anti-HBs) according to annual distribution, age groups, and sex. The HBsAg positivity rate was 7.0% (75,596/1,095,561; p=0.001): 7.4% (96,532/944,077) in the 25 years and over age group and 4.0% (358/9,268 and 325/10,864) in the under 5 and 13-24 year age groups. The positivity rates of the other HBV serological markers were as follows: anti-HBc total was 37.0% (34,377/93,711; p < 0.001), anti-HBc IgM was 2.4% (5,661/239,237; p=0.05), and anti-HBs was 37.0% (76,302/206,138; p ≤ 0.001). Naturally acquired HBV immunity was detected in 25.7% (11,188/43,536) of patients in the 25 years and over age group, and 9.7% and 8.2% (113/1,158 and 541/6,522) among those under 5 years and 13-24 year age group, respectively (p < 0.001). Vaccine-induced immunity was 56.6% (656/1,158) in children under 5 years and 10.2% (4,425/43,536) among those 25 years and above (p < 0.001). Fifty-six percent (29,404/52,581) of patients were HBV seronegative; predominantly among patients in the 13-24 year age group (60.6%; (3,952/6,522)) and 25 years and over (56.3% (24,524/43,536)) (p=<0.001). The HBV infection seroprevalence remains high in South Africa, with Gauteng province having high intermediate endemicity. However, the HBV immunity gap has shifted from younger children to older children and adults.

Risk factors associated with Hepatitis B virus infection among pregnant women attending public hospitals in Addis Ababa, Ethiopia.

Hepatitis B Virus (HBV) infection is one of the serious public health problems worldwide and is a major cause of morbidity and mortality. Viral hepatitis during pregnancy poses problems like a high risk of maternal complications, mother-to-child transmission (MTCT), and challenges in the management of drugs. This study aimed to determine the magnitude of HBV infection and associated risk factors among pregnant women who attended public hospitals in Addis Ababa, Ethiopia. A multicenter prospective cohort study with a nested case-control was conducted from January 2019 to December 2020 in 5 public hospitals with maternal and child health care services in Addis Ababa. Three hundred pregnant women whose screening results for Hepatitis B surface antigen (HBsAg) were positive and another 300 with negative HBsAg were involved. Laboratory test results of blood samples and structured questionnaires were used to collect the data. Data was entered and analyzed by SPSS version 20 software using descriptive and logistic regression analyses. Of the 12,138 pregnant women who screened for HBsAg as routine antenatal care (ANC), 369 (3.04%) were positive. All of the sociodemographic characteristics did not significantly differ in both the cases and the controls. Body tattooing (AOR = 1.66; 95 CI: 1.008-2.728), multiple sexual partners (AOR = 2.5; 95% CI: 1.604-3.901), family history of HBV (AOR = 2.62; 95% CI: 1.239-5.547), and sharing sharp materials (AOR = 3.02; 95% CI: 1.87-4.87) were factors associated with increased risk of HBV infection. An intermediate endemicity of HBV infection was detected among pregnant women. Body tattooing, having multiple sexual partners, family history of HBV, and sharing sharp materials were significantly associated with HBV infection. Awareness creation on the mode of transmission and early screening of all pregnant women for HBsAg must be strengthened to minimize and control the spread of the infection.

Residual risk of mother-to-child transmission of HBV despite timely Hepatitis B vaccination: a major challenge to eliminate hepatitis B infection in Cambodia

BackgroundIn countries with intermediate or high hepatitis B virus (HBV) endemicity, mother-to-child transmission (MTCT) represents the main route of chronic HBV infection. There is a paucity of information on HBV MTCT in Cambodia. This study aimed to investigate the prevalence of HBV infection among pregnant women and its MTCT rate in Siem Reap, Cambodia.MethodsThis longitudinal study included two parts, study-1 to screen HBsAg among pregnant women and study-2 to follow up babies of all HBsAg-positive and one-fourth of HBsAg-negative mothers at their delivery and six-month post-partum. Serum or dried blood spot (DBS) samples were collected to examine HBV sero-markers by chemiluminescent enzyme immunoassay (CLEIA), and molecular analyses were performed on HBsAg-positive samples. Structured questionnaires and medical records were used to examine the risk factors for HBV infection. MTCT rate was calculated by HBsAg positivity of 6-month-old babies born to HBsAg-positive mothers and ascertained by the homology of HBV genomes in mother–child pair at 6-month-old.ResultsA total of 1,565 pregnant women were screened, and HBsAg prevalence was 4.28% (67/1565). HBeAg positivity was 41.8% and was significantly associated with high viral load (p < 0.0001). Excluding subjects who dropped out due to restrictions during COVID-19, one out of 35 babies born to HBsAg-positive mothers tested positive for HBsAg at 6 months of age, despite receiving timely HepB birth dose and HBIG, followed by 3 doses of HepB vaccine. Hence the MTCT rate was 2.86%. The mother of the infected baby was positive for HBeAg and had a high HBV viral load (1.2 × 109 copies/mL). HBV genome analysis showed 100% homology between the mother and the child.ConclusionsOur findings illustrate the intermediate endemicity of HBV infection among pregnant women in Siem Reap, Cambodia. Despite full HepB vaccination, a residual risk of HBV MTCT was observed. This finding supports the recently updated guidelines for the prevention of HBV MTCT in 2021, which integrated screening and antiviral prophylaxis for pregnant women at risk of HBV MTCT. Furthermore, we strongly recommend the urgent implementation of these guidelines nationwide to effectively combat HBV in Cambodia.

Sero-Prevalence of Hepatitis B Virus and Associated Factors among Pregnant Women’s Attending Antenatal Clinics in Public Hospitals of Hawassa City, Southern, Ethiopia, 2021. Cross Sectional Study

Introduction: Viral hepatitis caused by the hepatitis B virus (HBV) is now recognized as a growing worldwide health issue. A significant global public health issue is the estimated 350 million people who have been diagnosed with chronic HBV infection and the 686,000 deaths that occur each year. Since HBV infected pregnant women are at risk of transmitting virus to their babies, knowing prevalence of HBV and its risky factors in the area is very essential. Providing area-specific hepatitis B burden data to enable health policymakers to develop suitable and cost-effective HBV infection prevention strategies. Objective: The objective of this study was to determine the sero-prevalence of HBV and related factors in pregnant women attending ANC at hospitals in Hawassa City, 2021. Method: From May 20 to July 30/2021, 320 pregnant women were the subjects of a hospital-based cross-sectional research at the Public Hospital in Hawassa City. SPSS version 25.0 was used to enter and analyze the data. HBV prevalence was determined using descriptive statistics; bivariate and multivariate logistic regression analysis was utilized to find independent predictors of HBV status at p-value &lt;0.05. Results: Overall Sero-prevalence of HBV infection was [6.9% (95% CI (6.6%, 7.2%)]. History of transfusion, history of vulvar ulcer, and contact with patients who had jaundice were all independently predictive of HBV in the study area (AOR = 19, 95%CI, (2.1-27.1), AOR = 14.8 (95%CI, 1.12-19.4), and AOR = 12.7.6[12-13.4], respectively). Conclusion: In the studied area, intermediate endemicity of HBV prevalence was found. To decrease HBV endemicity, it is crucial to raise awareness about HBV transmission specially contact history of jaundice individual, vulvar ulcer and conduct early screenings at blood donor sites before transfusion

Knowledge and Prevention of Vertical Transmission of Hepatitis B Infection: A Cross-Sectional Study among Pregnant Females in Varanasi, India.

300 million individuals worldwide suffer from chronic HBV infection. India, an intermediate endemicity zone, has a 3-4% HBsAg prevalence in the general population and 0.9-11.2% among pregnant women. As 95% of infantile infections progress to chronicity, vertical transmission is a vital intervention area. To assess the knowledge of pregnant women and post-natal mothers concerning Hepatitis-B infection transmission and prevention. A cross-sectional study was conducted with 143 participants (124 pregnant females and 19 postnatal mothers) attending the antenatal clinic at the rural block primary health center. A semi-structured questionnaire was used. Blood samples were evaluated for HBsAg using RAPIKIT. SPSS-22 was utilized for descriptive statistical analysis. 91.6% of respondents had heard of Hepatitis. 1.4% stated that it can be caused by a virus, whereas 40% identified consumption of oily, spicy, and unhygienic food as causative. 67.1% of respondents underwent blood tests but could not specify what they were screened for. 5.2% were HBsAg positive. ~40% were aware of vertical transmission. 59.4% of respondents were unaware of any preventive modality, and 7.7% said vaccination is preventive. 97.9% had never been counseled during their antenatal period by health workers. 41.1% said that their newborns were vaccinated within 24 hours of birth. Findings emphasize the paucity of knowledge possessed by pregnant women and post-natal mothers concerning Hepatitis B causation, transmission, and prevention regardless of age, education, or socioeconomic status. Misconceptions were prevalent, and counseling was inadequate.

1240. Hepatitis A in Latin America and the Caribbean: a Systematic Literature Review on Endemicity Patterns and Immunization Programs

Abstract Background In 2019, hepatitis A virus (HAV) infections caused around 39,600 deaths worldwide. Age-specific seroprevalence is used as a marker to classify endemicity. In countries with intermediate endemicity, WHO recommends universal HAV vaccination for children ≥1 year considering local disease burden and cost-effectiveness analyses. This review aimed to describe the endemicity patterns and HAV immunization programs in Latin America and the Caribbean (LAC). Methods We conducted a systematic literature review using MEDLINE, Embase, CENTRAL, CDRS, Lilacs, and Scopus from January 2005 to December 2021. Additionally, we searched grey literature, including Pan American Health Organization/WHO country profiles and official government websites in January 2022. The main outcomes were HAV seroprevalence and characteristics of HAV immunization programs. Results We identified 30 studies containing data on HAV seroprevalence in LAC and 13 records from grey literature on HAV vaccination program. As of January 2022, among 33 countries, 8 had public universal childhood HAV vaccination program and 12 had programs for at least one population at-risk (Figure 1 and Table 1). Only 7 countries had seroprevalence data available (Figure 2). Using WHO criteria, 5 countries were classified as intermediate endemicity; 2 have already introduced HAV vaccination in the NIP (Brazil and Colombia) and 3 have not introduced yet (Bolivia, Mexico, and Peru). In Argentina and Brazil, studies conducted in certain populations at risk, such as men who have sex with men and healthcare workers aged between 20-40 years, showed higher susceptibility to infection (seroprevalence: 40%-60%). Figure 1.Hepatitis A routine immunization schedule in national immunization programs in Latin America and the Caribbean, 2022 a Available for Guatemalan Social Security Institute (employed people in formal sector), which represents 17% of total population. b Countries that included in national immunization program for at least one population at risk Table 1.Characteristics of hepatitis A immunization programs in Latin America and the Caribbeana Populations at risk: 2-dose schedule; b Partial introduction in 2014 in endemic areas; c only available for Guatemalan Social Security Institute (formally employed population), which represents 17% of total populationFigure 2.Hepatitis A endemicity level in studies conducted in Latin America and the Caribbean based on WHO classification criteriaa general population; b premarital exam; c health care workers; d children school; e liver cirrhosis; f national survey; g samples from labs, h beauticians; i population-based survey; j chronic HCV infection; k rural settlement; l low socioeconomic groups; m chronic HCV infection; n men who have sex with men/ transgender women. Mantovani 2015 and Pereira 2016 are included in the review and not showed here (description of prevalence &amp;lt; 5 y) Conclusion Eight countries had universal HAV vaccination program and 12 offered for at least one population at-risk. LAC countries where HAV seroprevalence was available showed predominance of intermediate endemicity. Bolivia, Mexico, and Peru would benefit from universal childhood vaccination, and Argentina and Brazil should evaluate increasing susceptibility among adults at-risk to expand access to vaccination. In countries without recent data, surveillance of acute cases/outbreaks and seroprevalence studies are needed to guide the HAV vaccination implementation. Disclosures Cintia I. Parellada, MD, PhD, MSD Brazil: Employee of MSD Brazil, a subsidiary of Merck &amp; Co., Inc.,|MSD Brazil: Stocks/Bonds Emilia Prieto, MD, MSc, MSD Colombia: Employee of MSD Colombia, a subsidiary of Merck &amp; Co., Inc.,|MSD Colombia: Stocks/Bonds Cristina Carias, PhD, Merck &amp; Co., Inc.: Employee|Merck &amp; Co., Inc.: Stocks/Bonds Martha Carolina Valderrama, MD, Msc, IQVIA: Advisor/Consultant|IQVIA: Employee of IQVIA who received funding to execute this study Daniel Samacá-Samacá, Msc, IQVIA: Advisor/Consultant|IQVIA: Employee of IQVIA who received funding to execute this study Fabian Hernandez, BSPharm, Msc, IQVIA: Employee of IQVIA who received funding to execute this study Homero Monsanto, PhD, Merck &amp; Co., Inc.: Employee.

Prevalence of Hepatitis B infections and associated risk factors among pregnant women at Hawa Memorial Saviour Hospital in the Abuakwa North Municipality, Ghana

Background: Hepatitis B virus infection is one of the most common public health problems worldwide. Over one million people globally are estimated to die annually of virus-related chronic liver disease. The routes of transmission include perinatal transmission at birth, unprotected sexual intercourse, injecting drugs, contaminated blood, and blood products, and through medical practices. In Ghana, there is a paucity of information about the prevalence of the Hepatitis B virus, its risk factors, knowledge, attitude, and practices among the population including pregnant women who are at higher risk of the infection. Methodology: This was a cross-sectional study conducted among a sample of 260 systematically selected pregnant women attending an Antenatal Clinic at Hawa Memorial Saviour Hospital in the Abuakwa North Municipality of the Eastern Region of Ghana. Demographic characteristics, risk factors, and respondents’ perceived knowledge, attitudes and practices on the disease were evaluated using a standardized structured questionnaire. Blood samples of participants were taken to determine their Hepatitis B seroprevalence using the HBV detection kit set device after the questionnaires were administered. Descriptive statistics were used to report on variables of key, while a Person’s Chi-Square test was employed to determine the association between selected variables and an outcome variable. Results: The seropositivity of Hepatitis B among pregnant women was 4.6% which is an intermediate endemicity. The majority of the study participants were between the age group 30-34years (35.38%). However, the study found that the infection rate was highest among age groups 20-24years (12%). The sociodemographic characteristics of the respondents in the study showed that only marital status (p&lt; 0.05) was significantly associated with Hepatitis B infection. There was inadequate knowledge among respondents which was largely due to a low level of education on Hepatitis B infection at the Antenatal clinic of the Hospital. The study also found that respondents that are categorized as having low-risk levels had a seropositivity rate of 5.3% which is higher than the overall seropositivity rate of the study, and even though most people had good practices, Hepatitis B infection was highly prevalent among them. Conclusions: The study showed that Hepatitis B virus infection was highest (12%) among the age groups of 20-24 years. Only the respondents’ marital status (p&lt;0.05) was noted to be significantly associated with infection. The detected inadequate knowledge, attitudes, and practices in the transmission and prevention of the disease call for full attention to the risk factor among respondents in the development of relevant policies and public health programs to address this important public health problem.

Age Group-Specific Assessment of Changing Seroepidemiology of Hepatitis A Virus Infection in North India.

Introduction Routine immunization against hepatitis A virus (HAV) infection has not been warranted in India, but an epidemiological shift from hyperendemicity to intermediate endemicity has been detected in recent years. The present studywas planned to gather theage group-specificseroprevalence data of hepatitis A IgG antibodies in various age groupsandevaluateany early trends of seroepidemiological shift. Method This was a hospital-based cross-sectional study. The detection of IgG antibodies for hepatitis A was done using an HAV Ab kit (Dia.Pro, Milan, Italy) in sera of individuals from >1 to 80 years of age and consenting to participate. Data on sociodemographic factors and potentially predisposing factors of HAV was collected on a predesigned questionnaire. At the time of final analysis, patients were divided into three groups children one to <18 years, adults ≥18 to <60 years, and old ≥60 to 80 years for comparative analysis. Result A total of 1,250 patients were included in the final analysis (129 children, 928 adults, and 193 old). The male/female ratio of the study participants was 1.4:1. The majority (85%) of them came from rural and semi-urban areas. They generally had lower socioeconomic status (SES) with poor literacy rates. Most of the enrolled cases(n=800/1,250, 64%) reported the use of groundwater, and 58.7% (n=734/1,250) consume water without any purification. Of the study participants,90.8% reported the use of toilets for defecation, and 96.7% of the cases use soap for handwashing after defecation. The majority of adult (90%) and old age (99%) participants were seropositive for anti-HAV IgG antibodies as compared to children (80%). No significant differences were observed in the seropositivity rates and the SES class of the study participants. Conclusion About 20% of children did not have anti-HAV IgG antibodies in the present study, indicating that they are not exposed to HAV. This could bebecause of their better living conditions such as the availability of safe drinking water and improved sanitation and hygiene. We support the current guidelines of the Indian Academy of Pediatrics (IAP), which recommends immunization for hepatitis A vaccination at 12 months of age. Adult vaccination is notneeded in North India.

Effectiveness of prophylaxis for hepatitis B in infants born to mothers serologically positive in Benghazi Medical center

Background: The seroprevalence of HBs Ag among the general population in Libya was found to be 2.2 %. Libya is therefore considered an area of intermediate endemicity for hepatitis B. vertical transmission is considered as the main route of spread of this infection. Trans placental (intra-uterine) transmission is presumed to cause the minority. Risk factors for transmission of HBV include maternal HBe Ag positivity, HBs Ag titer, and HBV viral load. Active immunization with hepatitis B vaccine (Hep. B vaccine), and hepatitis B immunoglobulin (HBIG) is 85-95% effective in preventing the disease. The objective of the study: To assess the effectiveness of hepatitis B vaccine and hepatitis B immunoglobulin in the prevention of the Hep. B. virus transmission and to study the factors that affected the immune response of the newborn babies of mothers with hepatitis B positive infection during pregnancy. Patients &amp; Methods: A longitudinal cross-section study included 40 babies born to mothers with hepatitis B during the period from 1.1.2017 To 1.3.2019 at Benghazi Medical Center. The newborn babies have been immunized with Hepatitis BIG and Hepatitis B vaccine at birth, and further 3 doses of hep. B vaccine and HBIG. Multivariable analyses were done to assess the statistical significance associated with responders and nonresponders to HB immune prophylaxis. Results: all babies were negative for hepatitis Bs Ag in 40(100%), 35 (88%) their viral load was 10 mlIU/ml) in More than two-thirds (60%) and (63%) of infants at 9 months and 12 months respectively. Birth weight &gt;2.5 kg was significantly associated with immune response &gt;10 mIU/ml, whereas, Maternal viral load, time of administration of HBIG, and hep. B vaccine, gestational age, mode of delivery, type of feeding were statistically not significant. Conclusion: the study reported that all the newborn babies were negative for hepatitis B sAg after delivery, more than two-thirds of the babies were responders to immune-prophylaxis, and birth weight of &gt;2.5kg was significantly related to high immune-response.

Hepatitis B, C, and delta in the general population in Mayotte: hepatitis B as a major public health concern

BackgroundLocated in southwestern Indian Ocean, Mayotte is a French territory, with a very specific demographic, social and health context. To date, epidemiological data on infections by hepatitis B (HBV), C (HCV), and delta (HDV) viruses in Mayotte have been sparse. We aimed to estimate, in the 15–69-year-old general population living in Mayotte, the prevalence of infections by hepatitis B (HBV), C (HCV), and delta (HDV) viruses and the distribution of HBV status: current infection with positive HBs antigen (Ag); resolved infection with positive HBc antibodies and negative HBsAg; immunisation by vaccination with only positive HBs antibodies; and no infection/no immunisation with negative markers. We also described the characteristics of infected people and assessed the determinants of lifetime HBV infection.MethodsThe Unono Wa Maore survey, implemented in a random sample of the general population in 2018–2019, consisted of an at-home collection of epidemiological data and venous blood samples. Detection of hepatitis B, C, and delta serological and molecular markers was performed.ResultsAmong 5207 eligible people, 4643 responded to the questionnaire (89.2%), with 2917 being tested for HBV and HCV (62.8%). Estimated HBV status was as follows: current infection 3.0% (95% confidence interval [CI]: 2.3–3.9%) (n = 76); resolved infection 27.8% (95% CI: 25.8–29.9); immunisation by vaccination 27.7% (95% CI: 25.9–29.7); and no infection/no immunisation 41.5% (95% CI: 39.3–43.7). One participant was positive for HDV antibodies (Ab) (0.65%) with a negative HDV-RNA viral load. The risk of lifetime HBV infection was higher in men (adjusted prevalence ratio (aPR): 1.55, 95% CI: 1.29–1.89); in people aged 30–49 years (aPR: 3.83, 95% CI: 1.49–9.81) or 50–69 years (aPR: 4.52, 95% CI: 1.77–11.53) compared to those under 20; in individuals who reported no condom use during their first sexual intercourse (aPR: 1.46, 95% CI: 1.01–2.14); and in those living in Dembeni-Mamoudzou (aPR: 1.40, 95% CI: 1.09–1.80) compared to the West-Centre of Mayotte. Finally, six individuals were positive for HCV antibodies (0.21%), including three positive for HCV RNA.ConclusionsMayotte is an area of intermediate endemicity for HBV and low endemicity for HCV and HDV. With a prevalence of HBsAg 10 times higher than in mainland France, a high proportion of people susceptible to HBV infection, and a demographic, health, and social context that may favour its transmission, hepatitis B is a major public health concern in Mayotte.